ECL vs RNA · P/E 35, rev $8.48B vs rev $22.6M
Ecolab Inc (ECL) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
Ecolab Inc (ECL) is a specialty chemicals company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported ECL revenue for 2026-06-30 was $8.48B. Net income was $967.5M. ECL currently screens at market cap $72.05B and trailing P/E 34.6.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
ECL currently screens at market cap $72.05B and trailing P/E 34.6. RNA currently screens at market cap $217.5M.
Not investment advice. Open the ECL and RNA stock pages for the full models.
Not investment advice.